Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caspar Liesenhoff

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Klinische Monatsblatter Fur Augenheilkunde|February 27, 2024
Andreas Ohlmann, Caspar Liesenhoff, Victor Brantl
Neurosurgical Review|May 27, 2021
Improved potential quality of intraoperative transcranial motor-evoked potentials by navigated electrode placement compared to the conventional ten-twenty systemArthur Wagner, Sebastian Ille, Caspar Liesenhoff, et al.
International Journal of Molecular Sciences|August 26, 2023
Endogenous Galectin-1 Modulates Cell Biological Properties of Immortalized Retinal Pigment Epithelial Cells In VitroCaspar Liesenhoff, Simon Martin Paulus, Caroline Havertz, et al.
International Journal of Molecular Sciences|August 14, 2025
Role of Endogenous Galectin-3 on Cell Biology of Immortalized Retinal Pigment Epithelial Cells In VitroCaspar Liesenhoff, Marlene Hillenmayer, Caroline Havertz, et al.
International Journal of Molecular Sciences|September 14, 2024
Galectin-1 Attenuates PDGF-Mediated AKT Signaling in Retinal Pigment Epithelial CellsMartina Bizzotto, Annabella Ostermaier, Caspar Liesenhoff, et al.
BMJ Open Ophthalmology|June 1, 2025
Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degenerationMichael Hafner, Ben Asani, Franziska Eckardt, et al.
Life (Basel, Switzerland)|November 27, 2025
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 31, 2025
Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phaseFranziska Eckardt, Michael Hafner, Anna Lorger, et al.
Klinische Monatsblatter Fur Augenheilkunde|December 15, 2025
[Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration]Caspar Liesenhoff, Daniel Krause, Franziska Eckardt, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Klinische Monatsblatter Fur Augenheilkunde|February 27, 2024
Andreas Ohlmann, Caspar Liesenhoff, Victor Brantl
Neurosurgical Review|May 27, 2021
Improved potential quality of intraoperative transcranial motor-evoked potentials by navigated electrode placement compared to the conventional ten-twenty systemArthur Wagner, Sebastian Ille, Caspar Liesenhoff, et al.
International Journal of Molecular Sciences|August 26, 2023
Endogenous Galectin-1 Modulates Cell Biological Properties of Immortalized Retinal Pigment Epithelial Cells In VitroCaspar Liesenhoff, Simon Martin Paulus, Caroline Havertz, et al.
International Journal of Molecular Sciences|August 14, 2025
Role of Endogenous Galectin-3 on Cell Biology of Immortalized Retinal Pigment Epithelial Cells In VitroCaspar Liesenhoff, Marlene Hillenmayer, Caroline Havertz, et al.
International Journal of Molecular Sciences|September 14, 2024
Galectin-1 Attenuates PDGF-Mediated AKT Signaling in Retinal Pigment Epithelial CellsMartina Bizzotto, Annabella Ostermaier, Caspar Liesenhoff, et al.
BMJ Open Ophthalmology|June 1, 2025
Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degenerationMichael Hafner, Ben Asani, Franziska Eckardt, et al.
Life (Basel, Switzerland)|November 27, 2025
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 31, 2025
Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phaseFranziska Eckardt, Michael Hafner, Anna Lorger, et al.
Klinische Monatsblatter Fur Augenheilkunde|December 15, 2025
[Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration]Caspar Liesenhoff, Daniel Krause, Franziska Eckardt, et al.
Pageof 1